GlassScriptPhysician profile
Kathryn P Edwards
NPI 1326197039
$2,807.41
in general payments reported to CMS, 2019-2025
22 companies · $897 in 2025
The $897 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.59 · 2020: $29.53 · 2021: $210 · 2022: $376 · 2023: $607 · 2024: $634 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $472.19 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $355.10 | 2021-2025 | Dupixent |
| Genzyme Corporation | $351.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $320.19 | 2021-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $188.58 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Novartis Pharmaceuticals Corporation | $175.87 | 2023-2025 | |
| Csl Behring | $163.57 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Stryker Corporation | $125.61 | 2022 | |
| Optinose US, INC. | $122.18 | 2023-2024 | |
| Genentech USA, INC. | $99.65 | 2019-2025 | Xolair |
| Alk-Abello, INC | $74.62 | 2021-2022 | |
| Aerin Medical INC. | $66.31 | 2024-2025 | |
| Amgen INC. | $61.39 | 2023-2025 | Tezspire |
| Kaleo, INC. | $59.54 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $41.43 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $30.42 | 2022-2025 | Adbry |
| Pharming Healthcare, INC. | $26.00 | 2022 | |
| Biocryst US Sales Co., LLC | $17.70 | 2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $16.34 | 2023 | Ryaltris |
| Abbvie INC. | $14.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.